Log in

MBS reimbursement for MPN sequencing

8 Jul 2022 3:45 PM | Valerie Orton (Administrator)

HSANZ and a number of other societies have been lobbying for the reimbursement of NGS for myeloproliferative neoplasm. I’m pleased to say that this has been approved for ET/ PV (item 73398) and transplant eligible myelofibrosis (item 73399). Please contact your friendly haematopathology service for details about testing and availability. 

Best wishes
Steven Lane – on behalf HSANZ


Haematology Society of Australia and New Zealand (HSANZ)
145 Macquarie Street, Sydney NSW 2000
Tel: 02 8097 8114


Copyright © 2020 Haematology Society of Australia & New Zealand (HSANZ). All Rights Reserved.

Powered by Wild Apricot Membership Software